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Influence of HLA-A, HLA-B, and HLA-DR
matching on rejection of random corneal grafts
using corneal tissue for retrospective DNA HLA
typing
Marjolijn C Bartels, Henderikus G Otten, B Elske van Gelderen, Allegonda Van der Lelij
Abstract
Aim—To establish if coincidental HLA-A,
HLA-B, and HLA-DR tissue matching is
associated with a reduced likelihood of
corneal graft rejection.
Methods—Organ culture preserved ran-
dom donor corneas were used for pen-
etrating keratoplasty (PKP). Corneal
tissue from all graft recipients and donors
or blood samples from recipients after
repeated transplantation were obtained in
order to perform retrospective molecular
HLA typing. A group of 21 recipients with
a rejection episode (cases) after corneal
transplantation was compared with a con-
trol group of non-rejectors (n = 43). 31
graft recipients were considered as high
risk patients. The influence of HLA-A,
HLA-B, and HLA-DR matching on rejec-
tion free graft survival time was analysed
with Kaplan-Meyer statistics and Cox
regression.
Results—A prolonged rejection free sur-
vival time was observed in graft recipients
with one or two HLA-A matches (log rank
test, p = 0.034). This eVect was also
observed in high risk graft recipients with
one or two HLA-DR matches (log rank
test, p = 0.030).
Conclusions—Coincidental HLA-A and
HLA-DR matches were observed and
associated with a prolonged rejection free
survival time in the total group and in the
high risk group, respectively. These re-
sults support the beneficial eVect of
prospective HLA-A and HLA-DR typing
upon corneal graft survival.
(Br J Ophthalmol 2001;85:1341–1346)
Corneal grafting is often a successful proce-
dure.1 In contrast with transplantation of other
solid organs, no systemic immunosuppressive
agents are needed to prevent allograft rejec-
tion.2 In avascular corneas, graft survival
results of 85–95% were reported after 1 year of
follow up.1 3 Nevertheless, immunological allo-
graft rejection is reported to be the leading
cause of corneal graft failure.3 4 The incidence
of immune mediated graft rejection and failure
is increased in high risk patients having corneal
vascularisation or a history of graft rejection.5–8
It might be expected that corneal graft survival
in high risk cases would increase after prospec-
tive human leucocyte antigen (HLA) class I
matching of donor and recipient,5 9–12 in
accordance with HLA matching for increased
graft survival of other solid organs.13 14 How-
ever, the role of HLA matching in reducing
corneal graft failure could not be confirmed by
all studies.3 15–18 A beneficial role of HLA-A and
HLA-B matching can be explained by the find-
ing that mismatched HLA class I antigens are
immunogenic.19 20 HLA class I antigens are tar-
gets for rejection by CD8+ cytotoxic T
lymphocytes.21
Organ culture preservation of donor corneas
was shown to contribute to a reduction in the
amount of HLA class II bearing Langerhans
cells,22–24 resulting in reduced antigenicity of
the corneal graft.19 25 This may lead to a
decreased incidence of rejection. HLA-DR
(class II) matching in cornea transplantation
showed beneficial eVects26 27 and an adverse
eVect in another study.28 This controversy may
be explained partly by inadequacy of serologi-
cal HLA-DR typing techniques.29
Although HLA matched corneal grafts were
rarely used in patients at high risk of rejection
at the University Medical Centre of Utrecht,
Netherlands, a relatively high success rate of
corneal transplants was observed over the last 5
years.30 With the recent availability of DNA
based typing techniques29 31 32 it is possible to
perform HLA-A, HLA-B, and HLA-DR typ-
ing of recipients and donors retrospectively
and accurately.33–36 The aim of this retrospec-
tive study was to examine whether diVerences
exist with regard to molecular HLA-A,
HLA-B, and HLA-DR matching and to rule
out coincidental HLA matching between
corneal graft recipients, with versus without
immune mediated graft rejection.
Patients and methods
PATIENTS
Between February 1995 and December 1997
248 consecutive patients underwent PKP with
random corneal grafts at the University Medi-
cal Centre of Utrecht, Netherlands. Patient
charts were revised for age, sex, use of systemic
immune suppression, a history of glaucoma or
herpes simplex keratitis (HSK), tear film insuf-
ficiency, number of previous grafts, indication
for transplantation, degree of stromal vascu-
larisation of the recipient cornea at the time of
PKP, additional surgical procedures during
PKP, any rejection episodes, and the final out-
come of the corneal graft. In the category of
patients with a history of glaucoma we
included patients with ocular hypertension or
primary open angle glaucoma (POAG) based
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on use of antiglaucoma medication, neu-
ropathy with an excavation of the optical nerve,
defects in the visual field, a diagnosis of POAG,
or an intraocular pressure above 23 mm Hg.
Furthermore, information about the donors
and donor corneas was collected; age, sex, graft
size, and storage time of organ culture
preservation. High risk criteria for corneal allo-
graft failure were defined according to the
presence of two or more quadrants of deep
stromal vascularisation and/or previous immu-
nologically mediated allograft failure(s).9
Out of the group of 248 patients a case (n =
21) and control group (n = 43) were selected.
Cases were all transplant recipients undergoing
a rejection episode, according to strict criteria
described below (n = 23). Patients for whom it
was not possible to diVerentiate between
irreversible graft rejection and graft failure due
to other causes were not included. Patients in
whom no corneal tissue was available for DNA
isolation (n = 2, one patient grafted for Fuchs’
dystrophy and the other for HSK) were
excluded. The control group was formed out of
a group of patients with at least 1 year of follow
up after PKP and no episodes of graft
rejection. This group was matched for age and
sex. Patients with graft failure because of other
causes than rejection were not excluded as long
as their cornea could be evaluated for rejection
during the study period. Eight out of 43 grafts
failed irreversibly as a result of other causes
than graft rejection, two grafts failed as a con-
sequence of intractable glaucoma, and six
because of presumed slow endothelial decom-
pensation.
In the group of cases, 12 out of 21 (57%)
could be considered as high risk and in the
group of controls 19 out of 43 (44%).
Patient, donor, and graft characteristics of
cases and controls are presented in Table 1. No
significant diVerences were found between the
two groups with respect to these characteris-
tics. The indications for PKP are shown in
Table 2.
DIAGNOSIS OF REJECTION
The time between PKP and the first rejection
episode, not necessarily ending in graft failure,
was used to analyse graft outcome. The
diagnosis of immune mediated allograft rejec-
tion was based on generally accepted criteria.37
All corneal grafts had to become clear after
surgery and a diagnosis of rejection was not
made for at least 10 days after surgery.
Rejection episodes were not diagnosed during
a period of elevated ocular pressure. The pres-
ence of a “Khodadoust line” was considered a
pathognomonic sign of graft rejection. In the
absence of a Khodadoust rejection line, graft
rejection was diagnosed by the presence of cells
in the anterior chamber, in combination with
an increase in (partial) corneal thickness
and/or keratic precipitates limited to the graft.
For patients with a history of HSK, graft rejec-
tion, and recurrence of herpes simplex virus
(HSV) infection needed to be diVerentiated. If
no Khodadoust line was observed, additional
tests were needed to diagnose HSV infection.
Aqueous humour was obtained by paracentesis
of the anterior chamber to determine intraocu-
lar antibody production against HSV, ex-
pressed as the Goldmann-Witmer coeYcient
for HSV. Also, PCR analysis of HSV DNA was
performed38 to exclude an active ocular herpes
simplex infection. Herpes infected cases were
excluded from analysis in this study.
METHODS
Donor procurement and medical procedures
did not change during the study period. All
donor corneas were obtained from Bio Implant
Service and the Dutch Eye Bank, Amsterdam,
Netherlands. The donor corneas were organ
culture preserved as described by Pels et al.39
All donor corneas were stored in organ culture
of Eagle’s minimum essential medium for at
least 7 days with a maximum of 27 days. PKP
procedures were performed by one of three
ophthalmic surgeons using similar surgical
techniques. All patients were treated with a
combination of prednisolone eye ointment
(0.5%, at bedtime) and local dexamethasone/
gentamicin eye drops (0.1%, six times daily)
after surgery, for 4 weeks. At least 1–1.5 years
after PKP, dexamethasone eye drops were
applied and gradually tapered oV. If PKP was
combined with a cataract extraction or removal
of an intraocular lens, additional eye drops
were given, containing a non-steroid anti-
inflammatory drug (0.1%, four times daily)
during the first 3 months after surgery.
Rejection reactions were treated with hourly
applications of prednisolone acetate 1% eye
drops and three periocular injections with
0.1% dexamethasone, given every other day.
Graft rejection has led to irreversible graft fail-
ure in nine out of 21 cases.
Table 1 Clinical characteristics of recipients and donors from the case and control group
Cases Controls
Number 21 43
Age (years): mean (range) 57.2 (29–79) 51.6 (11–83)
Male:female ratio 1.0:1.1 1.0:1.0
Use of systemic immune suppression 1 1
History of ocular hypertension or POAG 6 (28.6%) 9 (20.9%)
History of HSK 7 (33.3%) 14 (32.6%)
Tear film insuYciency 2 (9,5%) 3 (7.0%)
Number of previous grafts:
0 15 (71.4%) 35 (81.4%)
1 4 (19.0%) 8 (18.6%)
>1 2 (9.5%) 0 (0%)
Vascularisation of recipient cornea 11 (52.4%) 15 (34.9%)
Additional procedures:
Cataract extraction 3 (14.3%) 9 (20.9%)
Synechiolysis 3 (14.3%) 4 (9.3%)
Iris reconstruction 1 (4.8%) 2 (4.7%)
Donor age (years): mean (range) 69.0 (20–89) 67.8 (16–86)
Donor sex; male:female ratio 1.7:1.0 1.9:1.0
Time in culture medium (days): mean (range) 15.8 (7–23) 15.9 (10–27)
Graft size (mm): mean (range) 7.5 (6.5–8.0) 7.5 (5.5–8.0)
Table 2 Indications for PKP of cases and controls
Indication for PKP Cases Controls
HSK 7 12
Allograft failure 6 8
Keratoconus — 11
Pseudophakic BKP 2 5
Corneal ulcers 4 3
Trauma 2 2
Fuchs’ dystrophy — 2
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DNA TYPING FOR HLA
Corneal tissue was used for retrospective DNA
HLA typing. For this purpose, corneal tissue of
the recipients and corneal rims of donor
corneas were collected at the time of surgery
and stored frozen (at −80°C). After repeated
transplantation blood samples containing per-
ipheral blood mononuclear cells were taken
from recipients to obtain DNA. Corneal
tissues and blood derived cell suspensions were
subjected to DNA extraction using the Qiagen
DNA extraction kit (Boehringer, Mannheim,
Germany) for blood and tissues, according to
the manufacturer’s instructions. DNA solu-
tions were stored at −80°C until further ampli-
fication. The diagnosis of rejection at the end
of the follow up was made before the HLA typ-
ing was known. HLA typing was done without
knowledge of graft outcome. This molecular
typing of HLA-A, HLA-B, and HLA-DRB1
(all low resolution) was performed according
to a reverse hybridisation line probe assay as
described by the manufacturer of InnoLiPa
(Innogenetics, Gent, Belgium).40
Typing data were available in all 64 donor/
recipient pairs for HLA-DR. For HLA-A and
HLA-B one and five pairs were not available
respectively, owing to shortness of donor DNA
(n = 2), technical problems with PCR (n = 1),
and problems with analysing the Lipa test
results for HLA-B (n = 3). Analysis was
performed both on the broad HLA typing level
(A1, A2, A3, A9, A10, A11, A19, A28, B5, B7,
B8, B12, B13, B14, B15, B16, B17, B18, B21,
B22, B27, B35, B37, B40, B41, B42, B53, B70,
DR1, DR2, DR3, DR4, DR5, DR6, DR7,
DR8, DR9, DR10) and split typing level (splits
from A9, A10, A19, A28, B5, B12, B16, B17,
B21, B22, B70, DR2, DR3, DR5, DR6).
ANALYSIS AND STATISTICS
Comparability of patient, donor, and graft co-
variates between cases and controls were
analysed using the ÷2 test for categorical
variables and the independent T test for
continuous covariates. To analyse rejection free
graft survival, cases and controls were subdiv-
ided into a group with and a group without
matched HLA subtypes. The group with
matches consisted of cases and controls with
one or two matches of HLA-A, HLA-B, or
HLA-DR. Unadjusted survival probabilities
for the total group as well as the high and low
risk group were estimated using Kaplan-Meier
statistics and diVerences were assessed using
the log rank test.41 All tests were two sided and
a p value of less than 0.05 was taken as statisti-
cally significant.
To assess the clinical relevance of matching
we used Cox regression analysis estimating the
odds ratios (OR) and 95% confidence intervals
for the association between HLA matching per
HLA locus and duration of rejection free graft
survival, adjusting for confounding variables.
Covariates were chosen for inclusion in the
model if they were mildly correlated (p<0.20)
with rejection according to univariate analysis.
Using this selection criterion, only vascularisa-
tion of the recipient cornea was included in the
model (p = 0.12).
Results
The median follow up period of the control
group (n = 43) was 2.6 years (range 1–4 years).
The median time until rejection of the case
group (n = 21) was 9 months (range 12 days to
1 year and 11 months).
The maximum number of matches based on
split typing for a patient in this study was three,
which was detected in six controls and one
case. The distribution of HLA-A, HLA-B, and
HLA-DR split matches in cases and controls is
shown in Table 3. Recalculation of split HLA
DNA typing results into broad typing results
did not yield significant diVerences between
cases and controls with regard to HLA-A and
HLA-B matching. However, an increased
amount of broad HLA-DR matches was found
compared to the amount of split HLA-DR
matches in four cases.
Corneal graft recipient-donor pairs with
HLA-A matches had a longer rejection free
graft survival compared with corneal grafts
without HLA-A matches (log rank test, p =
0.034, Fig 1). We observed a trend towards a
prolonged rejection free graft survival with
increasing numbers of HLA-A matches. No
diVerence was observed in rejection free graft
survival time between cases and controls with
respect to HLA-B matches (Fig 2) and
HLA-DR matches (Fig 3).
Analysing rejection free graft survival for the
high risk (n = 31) and low risk (n = 33) group
separately, a stronger association between
longer rejection free graft survival and HLA-A
matching in the low risk group was found (log
rank test, p = 0.013). Graft survival was not
significantly longer with respect to HLA-B
matches in the high or low risk group (data not
Table 3 Degree of HLA-A,HLA-B, and HLA-DR
matching of the case and control group
No of split
matches Cases Controls
HLA-A 0 16 (76%) 21 (50%)
1 4 (19%) 15 (36%)
2 1 (5%) 6 (14%)
HLA-B 0 14 (74%) 30 (75%)
1 5 (26%) 9 (22.5%)
2 0 1 (2.5%)
HLA-DR 0 14 (67%) 25 (58%)
1 6 (29%) 17 (40%)
2 1 (5%) 1 (2%)
Figure 1 Kaplan-Meier curves indicating rejection free
survival of corneal graft recipients with one or two matches
at the HLA-A locus is significantly better than those with 0
HLA-A matches (log rank test, p = 0.030, n = 63).
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shown). Analysis of the HLA-A and HLA-B
matches together showed no eVect in the total
group or in the high risk group. However, we
observed a beneficial eVect of matching for
HLA-DR in the high risk group (log rank test,
p = 0.030, Fig 4).
According to Cox regression analysis, after
adjustment for vascularisation of the recipient
cornea, HLA-A matched transplants (one or
two HLA-A matches) were almost three times
less likely to reject than HLA-A unmatched
transplants (Table 4). HLA-DR matched
transplants were slightly, but not significantly,
less likely to reject (Table 4).
Discussion
The results showed that the presence of
HLA-A matches was associated with pro-
longed rejection free graft survival. When con-
sidering patients at high risk for rejection, a
beneficial eVect of HLA-DR matches was
shown. These HLA matches were found retro-
spectively in corneal graft recipients who
received random donor corneas at the time of
PKP.
Cases with and controls without an immune
mediated graft rejection were analysed to-
gether according to their rejection free graft
survival time. The first rejection episode, not
necessarily leading to graft failure, was used as
the end point of analysis. From an immuno-
logical point of view it is more appropriate to
use rejection free graft survival time rather than
time to immunological graft failure. Whether a
rejection episode will lead to graft failure is
dependent on treatment protocols of a rejec-
tion reaction used in diVerent transplantation
centres. Furthermore, each rejection episode
accelerates the postoperative loss of endothelial
cells, resulting in earlier graft failure.42 43
A major advantage of HLA DNA typing, as
used in this study, is that this method is less
prone to errors than serological typing tech-
niques.31 32 Discrepancy rates of 10–25% have
been reported for serological HLA-DR typing
in kidney transplantation.29 DNA can be
derived from any organic tissue, including cor-
neal tissue, which is easily obtained at PKP44
and nearly always available in contrast with
blood samples necessary for serological typing.
The diagnosis of an immune mediated graft
rejection is not always clearcut. Rejection and
recurrence of HSK can be impossible to distin-
guish clinically and may coexist.45 We excluded
patients for whom it was not possible to diVer-
entiate between graft rejection and HSK.
Patient compliance is of great influence on
graft survival.6 In our study topical steroids
were given for at least 1 year in all patients. All
patients with graft rejection within 1 year were
still using topical steroids. These data, how-
ever, are based on patient records and a contri-
bution of patient compliance to graft rejection
could not be fully excluded.
HLA-A and HLA-B antigens have been
identified on corneal epithelium, stromal cells,
and corneal endothelial cells.19 46 47 The HLA
class I antigens are targets for CD8+ cytotoxic
T cells in the process of graft rejection.21 Theo-
retically, matching for HLA-A and HLA-B
therefore would reduce the amount of target
Figure 2 Kaplan-Meier curves indicating the presence of
HLA-B matches did not improve rejection free survival of
corneal graft recipients (log rank test, p = 0.50, n = 59).
100
90
70
80
60
40
50
30
20
0
10
Time after PKP (years)
1 or 2 HLA-B matches
0 HLA-B matches
%
 r
ej
ec
ti
o
n
 f
re
e 
g
ra
ft
 s
u
rv
iv
al
0 1 2 3 4
Figure 3 Kaplan-Meier curves indicating the presence of
HLA-DR matches did not improve rejection free survival of
corneal graft recipients (log rank test, p = 0.92, n = 64).
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Figure 4 Kaplan-Meier curves indicating HLA-DR
matching in high risk recipients showed a beneficial eVect
on the rejection free graft survival (log rank test, p = 0.030,
n = 31).
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Table 4 Odds ratios of corneal graft rejection
OR* (95% CI)
HLA-A unmatched transplants J 0.34 (0.13–0.95)HLA-A matched transplants†
HLA-B unmatched transplants J 1.07 (0.38–2.97)HLA-B matched transplants‡
HLA-DR unmatched transplants J 0.69 (0.27–1.70)HLA-DR matched transplants§
*Adjusted for vascularisation of the recipient cornea.
†One or two matches for HLA-A.
‡One or two matches for HLA-B.
§One or two matches for HLA-DR.
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antigens, which could lead to a decreased inci-
dence of rejection. An accumulating number of
authors suggested that HLA-A and HLA-B
matching was associated with improved out-
come of corneal graft survival in high risk
recipients.5 9–12 15 33 48 49 These data on HLA-A
matching are in line with the results from our
study. However, other studies, including the
large Collaborative Corneal Transplantation
Study, failed to demonstrate a correlation of
HLA matches and graft survival.16–18 50 A
beneficial HLA-A matching eVect was ob-
served in all risk categories with a stronger
association in low risk cases by Boisjoly et al,11
which is in accordance with our findings. In
this study, HLA-B matches showed no signifi-
cant eVects on graft rejection. This might be
due to the overall low number of matches
observed in this study at the polymorphic
HLA-B locus. In previous studies, matching of
HLA-B showed a beneficial eVect on corneal
graft survival5 10 12 and an adverse eVect in oth-
ers.18 20
Despite the fact that HLA-DR is considered
to be important in renal transplantation,29 the
role of HLA-DR matching in corneal trans-
plantation remains controversial.49 51 Signifi-
cant beneficial eVects of HLA-DR matching in
high risk recipients were reported using RFLP
typing techniques,26 but a historical control
group was used. Japanese studies33 34 44 using
DNA typing techniques reported a strong ben-
eficial eVect of HLA-DP matching and no
eVect of matching for HLA-DR. This may be
explained by the overall low number of
HLA-DR matches reported by this group,
using donors and recipients from diVerent eth-
nic backgrounds. In our study, both donors
and recipients originated mostly from the
white population, and therefore from the same
gene pool. This may add to the explanation of
the high number of coincidental HLA-A and
HLA-DR matches we observed. In some stud-
ies, a beneficial influence of HLA-DR match-
ing could not be found in low or high risk
recipients,16 17 52 whereas in other studies an
adverse eVect was reported.28 51 However, in
these studies serological typing techniques
were used, which in general yield accurate
broad but not split typing results. In our study
HLA DNA typing included analysis of HLA
split antigens. A beneficial eVect of HLA-DR
matching in high risk recipients was shown.
After conversion of HLA-DR split to broad
antigens (data not shown), a significant eVect
of matching could no longer be found, which is
in line with the previously mentioned studies.
Expression of HLA-DR antigens carried on
Langerhans cells has been demonstrated
within normal corneal epithelium and stromal
layers.19 47 Migration and accumulation of
Langerhans cells in the central part of the cor-
nea, which is normally devoid of Langerhans
cells19 24 can be established by vascularisation
and inflammation.53 As a consequence of an
increased number of Langerhans cells in the
centre of the donor cornea, a rejection reaction
may be provoked.54 The beneficial eVect of
HLA-DR matching for high risk recipients as
reported in our study might be explained by a
higher number of Langerhans cells in the cen-
tral area of the cornea after transplantation in
this high risk group.
A drawback of this study is the overall low
number of included patients. Owing to the
random distribution of corneal grafts a rela-
tively small number of patients with more than
one match at HLA-A, HLA-B, or HLA-DR
loci was included. As a consequence it was not
possible to evaluate combinations of HLA-A
and HLA-B matches or to evaluate the eVect of
HLA-DR in the absence of any HLA-A or
HLA-B match.
Although the case and control group are
comparable with respect to the characteristics
mentioned in Table 1, the indications for
transplantation were not completely compar-
able, with Fuchs’ dystrophy (n = 2) and
keratoconus (n = 11) being present only in the
control group. One of the two excluded cases
(no donor corneal tissue available) was trans-
planted for Fuchs’ dystrophy; if this patient
had been included, the only remaining diVer-
ence would have been the indication of kerato-
conus. Analysis of rejection free graft survival
without considering these 11 patients showed
the same results for the high risk group (a
longer rejection free graft survival for HLA-DR
matched transplants). Furthermore, rejection
free graft survival was longer for HLA-A
matched transplants in the total group
(n = 52), despite the loss of power (p = 0.047).
We included controls with at least 1 year of
follow up. However, rejections are still ob-
served after 1 year. Therefore, further studies
with a longer follow up time will be needed to
show a beneficial long term outcome with
matching.
Organ culture preservation of donor cor-
neas, as used for all donor corneas in this
study, allows time to allocate corneas based on
HLA matching. Prospective DNA HLA typing
and transportation of donor corneas over long
distances to the most suitable recipient could
give logistical problems if short term preserva-
tion techniques, such as McCarey-Kaufman
medium, are used. The cost-benefit ratio of
providing matched corneal grafts should be
investigated in more detail. Especially in more
heterogeneous populations where less coinci-
dental HLA matches are expected, allocation
of matched donor corneas could be more diY-
cult but also more eVective in preventing
corneal graft rejection.
In conclusion, molecular typing of HLA-A,
HLA-B, and HLA-DRB1 is an accurate
method and oVers the possibility to perform
HLA typing at any time postoperatively, using
corneal derived DNA. Although all corneal
graft recipients received random donor cor-
neas, retrospectively a significantly higher
number of HLA-A matches was found, in
favour of recipients with longer rejection free
graft survival. Furthermore, a beneficial eVect
of matching for HLA-DR was shown for high
risk recipients. These results add to the
evidence that prospective molecular HLA-A
and HLA-DR typing has a beneficial eVect
upon graft survival.
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